Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) shares saw unusually-strong trading volume on Monday . Approximately 2,739,106 shares changed hands during mid-day trading, an increase of 98% from the previous session’s volume of 1,382,350 shares.The stock last traded at $6.71 and had previously closed at $6.27.

A number of brokerages have issued reports on AUPH. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 8th. Vetr upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $7.35 target price for the company in a research report on Tuesday, September 19th. Cantor Fitzgerald set a $14.00 price target on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 11th. Finally, BidaskClub downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Aurinia Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $9.79.

The stock’s 50-day moving average price is $6.22 and its 200 day moving average price is $6.72. The stock’s market capitalization is $560.18 million.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.10. The firm had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. On average, equities analysts forecast that Aurinia Pharmaceuticals Inc will post ($0.94) EPS for the current year.

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada raised its position in shares of Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 1,341 shares during the last quarter. Jane Street Group LLC bought a new stake in Aurinia Pharmaceuticals in the first quarter valued at approximately $155,000. Cutler Capital Management LLC bought a new stake in Aurinia Pharmaceuticals in the second quarter valued at approximately $184,000. Investment Centers of America Inc. bought a new stake in Aurinia Pharmaceuticals in the second quarter valued at approximately $184,000. Finally, Two Sigma Securities LLC bought a new stake in Aurinia Pharmaceuticals in the first quarter valued at approximately $240,000. Institutional investors own 27.76% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/10/02/aurinia-pharmaceuticals-inc-auph-sees-large-volume-increase.html.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.